My top 3 takehomes from #ACR18 are: @rheumnow 1. ACR is thinking about leaving ABIM & join ABAI to form a new board certifying body: ABAIR 2.Don’t worry too much about 5mg/kg/d HCQ dose- Dr M Petri still uses 6.5 mg/kg/d 3. No sig ⬆️ risk CV/DVT/PE with tofa and baricitib https://t.co/3YNhYltnfW

• Arthur Lau on Twitter: "Had a great time at #ACR18. What were your top 3 t…

#ACR18 @RheumNow abs 837 high dose flu vaccine in RA pts 2-3 times more likely to seroconvert vs standard dose. No increase in RA disease activity. ? translates to less flu?

#ACR18 @RheumNow abs 838 MDA5 pos DM-ILD. Hi dose steroids + tac + IV CycloP had 85%survival at 12m vs 33% in historic controls. Note 31%also had PEx. 90%had CMV reactivation. Impressive nevertheless. #RareDisease

Safety and Immunogenicity is one of nine educational videos available in the "Therapeutic Update: Biosimilars in Rheumatology" video series, sponsored by Sandoz, Inc. and now available on RheumNow. https://t.co/1vmnEJqOSi #biosimilars

• https://buff.ly/2yeKAPN

IgG4-related disease... almost completely unknown 10 years ago. "It is a perfect disease for rheumatologists to take care of." - Dr. John Stone #ACR18 @RheumNow

IgG4-RD histopathology consistent across organs: lymphoplasmacytic infiltrate, obliterative phlebitis, storiform fibrosis. #ACR18 @RheumNow

Pearls regarding IgG4-RD. Depressed complements commonly seen in renal involvement. #ACR18 @RheumNow https://t.co/m3oM4Aiuny

#IgG4 RD is an indolent disease but can present with severe weight loss (>20 pounds), largely due to pancreatic destruction. #ACR18 @RheumNow

Therapeutic potential of “glycoengineering" in autoimmune disease. Alter glycoforms of endogenous IgG -> reduce pathogenic impact of antibodies. Cell paper by Pagan JD et al https://t.co/UbBsE1jV4L Year in review basic science #ACR18 @RheumNow

• https://www.ncbi.nlm.nih.gov/pubmed/29275858

TLR8 aberrantly expressed on pDCs (cells that make type-I IFN) in SSc patients Depletion ameliorates disease https://t.co/SmDdpIU2I1 Ah Kioon et al Year in review basic science #ACR18 @RheumNow

• https://www.ncbi.nlm.nih.gov/pubmed/29321259

Stop by the ⁦@RheumResearch⁩ booth to get your ⁦@alhkim⁩ autographed flyers!!! #acr18 #rheumrockstars https://t.co/kVR4XB6ynO

Anti-GBM positivity did not predict relapse in Goodpasture's (but ANCA did predict relapse in GBM disease) Abs 826, Cleveland Clinic Roundup - Cush, Kavanaugh #ACR18 @RheumNow

Toci in SSc failed to achieve primary endpoint (modified Rodman skin score) Abs 898 Roundup - Cush, Kavanaugh #ACR18 @RheumNow

Canabinoids in vitro CB2 receptor drives inflammation Set the stage for discovery/development of future antagonists? Danger of over-interpretation on the street Abs 1068 Roundup - Cush, Kavanaugh #ACR18 @RheumNow

MTX for OA of the knee 12 months, 155 pts, endpoint=pain statistically significant improvement, probably not clinically meaningful consistent with prior reports Abs 428 Roundup - Cush, Kavanaugh #ACR18 @RheumNow